Advertisement

Immunotherapies Could Play Role in CALR-Positive Myeloproliferative Neoplasms (Video)

Data presented at the 2017 American Society of Hematology Annual Meeting support mutated calreticulin (CALR) as an MPN-specific tumor antigen, paving the way for immunotherapies targeting this mutation for patients with MPN.

 Cancer Network